Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute
ClinicalTrials.gov Identifier:
NCT01496807
First received: December 19, 2011
Last updated: August 17, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: March 2017
  Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)